Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iohexol SCHEMBL8844889 | 0.99 | CYP2C19 (1.00) | LMNACYP2C19HIF1AEGFRSRC | |
| Iodixanol SCHEMBL8845042 | 0.99 | LMNA (1.00) | LMNACYP2C19HIF1AEGFRSRC | |
| Iohexol SCHEMBL26501 | 0.99 | CYP2C19 (1.00) | LMNACYP2C19HIF1AEGFRSRC | |
| Iohexol SCHEMBL37920 | 0.99 | CYP2C19 (1.00) | LMNACYP2C19HIF1AEGFRSRC | |
| Iodixanol SCHEMBL37712 | 0.99 | LMNA (1.00) | LMNACYP2C19HIF1AEGFRSRC | |
| Iohexol SCHEMBL31722694 | 0.99 | CYP2C19 (1.00) | LMNACYP2C19HIF1AEGFRSRC | |
| Iodixanol SCHEMBL21546 | 0.99 | LMNA (1.00) | LMNACYP2C19HIF1AEGFRSRC | |
| Iohexol SCHEMBL8711982 | 0.97 | CYP2C19 (0.97) | LMNACYP2C19HIF1AEGFRSRC | |
| Iohexol SCHEMBL22719758 | 0.96 | CYP2C19 (0.95) | LMNACYP2C19HIF1AEGFRSRC | |
| Iohexol SCHEMBL3666605 | 0.96 | CYP2C19 (0.95) | LMNACYP2C19HIF1AEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | GUERBET (FR) | 2020-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836711-B2 | Method for the one-pot production of organo-iodinated compounds | TPO, NISCH, PPIP5K2 | LMNA 3525/4885CYP2C19 1408/4885HIF1A 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.